More codeine-containing products are experiencing shortages due to increased demand in the wake of the upschedule
In mid-April, AJP reported that Sanofi had seen a shortage of two of its codeine products, Panamax Co and Prodeine 24, due to an “unexpected increase in demand” following the withdrawal of other codeine-containing products on the market.
Due to this same demand, two more Sanofi products – Prodeine Xtra and Mersyndol Forte – are now experiencing shortages as well.
“We are continuing to see strong demand across our portfolio of nine Schedule 4 products which contain codeine,” a Sanofi spokesperson tells AJP.
“While five of those products remain in full supply, we are working hard to ensure more stock is delivered for four products in short supply.
“Of those in short supply, we understand that wholesalers still have some Panamax Co, Prodeine 24s and Prodeine Xtra.
“More of each product was dispatched to wholesalers last week and more will be available for dispatch again in the coming two weeks.
“There is also some Mersyndol Forte in wholesalers and we expect to have more ready to dispatch to in mid-late June.
“These changing stock levels coincide with a number of environmental factors including the withdrawal from sale of other codeine products by other suppliers. We are continuing to work hard to meet the changing needs of the market and normalise stock levels for all products.”
The TGA lists a resolution date of 30 May for Mersyndol Forte; 8 June for Prodeine Xtra; and 15 June for the Prodeine 24.
The Panamax Co shortage was expected to have been rectified by 1 May.
See more about medicines shortages at the Medicine Shortages Information Initiative.